Clinical data on CDK4/6 inhibitors and breast cancer: From metastatic to adjuvant treatment (notice n° 504540)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01505cam a2200157 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121083951.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Espié, Marc |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Clinical data on CDK4/6 inhibitors and breast cancer: From metastatic to adjuvant treatment |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 45 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The combination of hormone therapy and CDK4/6 inhibitors has become the reference treatment for hormone-dependent and HER2-negative metastatic breast cancers without rapidly progressive disease. Numerous phase II and III randomized trials with abemaciclib, palbociclib, and ribociclib have demonstrated a clear benefit in terms of progression-free survival and, in some cases, overall survival, both in first-line treatment and more advanced lines of treatment. Given that 20 to 30 percent of patients treated with hormone therapy alone are likely to subsequently relapse, it was only logical that these treatments should be offered in an adjuvant setting. Clinical trials are ongoing, although a study of patients at high risk of relapse has already produced positive outcomes on relapse-free survival. These results have led the FDA to approve the use of abemaciclib in combination with hormone therapy for this indication. |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 8 | 3 | 2022-05-01 | p. 157-165 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2022-3-page-157?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2022-3-page-157?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux